University of Saskatchewan

September 16, 2014   

Archived

  • U of S Spin-off gets $3 Million Boost to Develop Anti-inflammatory Drug     Nov 15, 2004
    IL Therapeutics, a U of S spin-off company located at Innovation Place, today received $3 million from the Western Life Sciences Venture Fund (WLS) to back research and development of a new drug treatment for Acute Respiratory Distress Syndrome (ARDS).
  • MCN Bioproducts Inc. Takes Award for Innovation     May 12, 2004
    MCN Bioproducts Inc., the brainchild of University of Saskatchewan researchers David Maenz, Henry Classen and Rex Newkirk, has been named winner of the third annual Innovation Place-Industry Liaison Office Award of Innovation.
  • U of S Signs Letter of Intent to Commercialize Treatment for Lung Injury Complications     May 06, 2004
    A letter of intent to commercialize a new drug treatment for Acute Respiratory Distress Syndrome (ARDS) has been signed between the University of Saskatchewan’s Industry Liaison Office (ILO) and IL Therapeutics Inc., a new start-up firm at Innovation Place on the U of S campus.
  • Seven U of S Researchers Nominated for Innovation Awards     Apr 14, 2004
    Seven University of Saskatchewan researchers whose work advances needle-free drug delivery, emergency stroke treatment and added value for canola were nominated for the third annual Innovation Place-Industry Liaison Office “Award of Innovation.”